

## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): L-(-)-moprolol L-(+)-tartrate salt (2:1).

Claim 2 (Original): Pharmaceutical composition for ophthalmic use, characterized in that it comprises L-(-)-moprolol L-(+)-tartrate (2:1) together with at least one pharmaceutically acceptable vehicle.

Claim 3 (Original): Pharmaceutical composition according to Claim 2, characterized in that it is in the form of a gel, an ointment or eyedrops.

Claim 4 (Currently Amended): Pharmaceutical composition according to Claim 2 [[or 3]], characterized in that the amount of L-(-)-moprolol is between 0.01 % and 20% by weight.

Claim 5 (Currently Amended): Pharmaceutical composition according to Claim 2 [[or 3]], characterized in that the amount of L-(-)-moprolol is between 1 and 8% by weight.

Claim 6 (Original): Process for preparing L-(-)-moprolol L-(+)-tartrate (2:1), characterized in that it includes the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol base, also dissolved in a suitable organic solvent, in a 2:1 molar ratio.

Claim 7 (Original): Process according to Claim 6, characterized in that the salt thus formed is isolated via precipitation and filtration.

Claim 8 (Currently Amended): Process according to Claim 6 [[or 7]], characterized in that the abovementioned organic solvent is ethyl alcohol.

Claim 9 (Original): Process according to Claim 8, characterized in that the salt is precipitated from the ethanolic solution via addition of ethyl ether.